CCDC92 is upregulated in diabetic kidney disease and contributes to lipid deposition and podocyte injury by altering lipid metabolism. Its deletion reduces lipid accumulation and improves podocyte integrity, indicating its potential as a biomarker and therapeutic target. This evidence concerns the gene CCDC92 and diabetic kidney disease.